MMMasakazu Matsushita

Masakazu Matsushita

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Masakazu Matsushita has a total of 69 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Clinical characteristics of giant cell arteritis with ocular involvement: A single-centre retrospective study

    by Toshio Kawamoto, Michihiro Ogasawara, Shuko Nojiri, Kyuta Kato, Yuko Matsuki-Muramoto, Masakazu Matsushita, Ken Yamaji, Naoto Tamura

    Objectives: To clarify the clinical characteristics of patients with ocular involvement in giant cell arteritis (GCA). Methods: This was an observational, single-centre, retrospective study of patients with GCA treated at Juntendo University Hospital between January 2012 and July 2023. The study involved 71 patients, including 21 with ocular involvement: 10 had fundus findings such as anterior ischemic optic neuropathy or central retinal artery occlusion (6 with permanent vision loss) and 11 without fundus findings. The demographic and clinical features of GCA were compared between patients with and without ocular involvement. Results: The temporal artery was found to be affected more frequently in cases with ocular involvement than in those without on positron emission tomography/computed tomography (P = .013) and vascular ultrasound (P = .02). The average number of signs and symptoms observed before diagnosis was higher in patients with ocular involvement than in those without (P < .001). The period from the appearance of ocular involvement to therapy initiation was shorter in patients with fundus findings than in those without (8.2 vs. 73.8 days; P = .032). Conclusions: Early imaging and early consultation with an ophthalmologist are important, as ocular involvement with fundus findings tended to occur earlier in GCA patients than without fundus findings.

  • Developments in clinical practice treating systemic lupus erythematosus—A single-centre retrospective longitudinal study in Japan

    by Kentaro Minowa, Yusuke Yanagimoto, Eitaro Yoshida, Ayako Makiyama, Makio Kusaoi, Masakazu Matsushita, Hirofumi Amano, Ken Yamaji, Naoto Tamura

    Objectives: To assess treatment patterns for systemic lupus erythematosus from 2012 to 2024 and evaluate corresponding changes in serological activity and relapse rates. Methods: We retrospectively reviewed medical records of 1705 patients with systemic lupus erythematosus treated at a single centre between 2012 and 2024. Temporal trends in therapeutic approaches, glucocorticoid (GC) use, and clinical outcomes were analysed. Results: Use of GC monotherapy declined from 58.3% in 2012 to 22.4% in 2024. Combination therapies (GC and hydroxychloroquine, with or without immunosuppressants) increased from 1.0% in 2015 to 41.6% in 2024, while biologics use rose from 0.9% in 2018 to 12.5% in 2024. Quadruple therapy (GC, hydroxychloroquine, immunosuppressants, and biologics) also expanded from 0.4% in 2018 to 6.2% in 2024. The mean GC dose decreased from 7.7 mg/day in 2012 to 4.6 mg/day in 2024, and the median dose, stable at 5 mg/day for many years, declined to 4.6 mg in 2023 and 4.2 mg in 2024. The proportion of patients with elevated serological activity steadily decreased. Flare rates peaked at 8.1% in 2016 but stabilised at ~4% after 2020. Conclusions: These findings suggest that improved disease control can increasingly be achieved in real-world practice while reducing long-term GC dependence.

  • SLE-DAS remission and low disease activity were similarly associated with patient-reported outcomes compared with definition of remission in SLE remission and lupus low disease activity state

    by Emi Nakanishi, Masakazu Matsushita, Kentaro Minowa, Kurisu Tada, Toshio Kawamoto, Makio Kusaoi, Hirofumi Amano, Takayuki Kon, Shinji Morimoto, Keigo Ikeda, et al.

    Objectives: The treat-to-target (T2T) approach for SLE has recently been proposed. However, the most suitable criterion for determining remission or low disease activity (LDA) using patient-reported outcomes (PROs) remains unknown. This study aimed to compare the relationship between PROs and various remission criteria, including the definition of remission in SLE (DORIS), SLE disease activity score (SLE-DAS) remission, lupus low disease activity state (LLDAS) and SLE-DAS LDA. Methods: A multicentre prospective study was conducted involving patients with SLE who visited Juntendo University and its affiliated hospitals between 2018 and 2024. A cross-sectional analysis was performed using surveys completed by physicians and patients. Multivariate analyses were performed to explore the relationship between PROs and remission/LDA criteria. Quality of life was evaluated using the medical outcomes study 36-item short-form health survey (SF-36) and EuroQol-5D. Results: This study included 334 patients. All remission and LDA criteria were significantly associated with the SF-36 physical component summary, with SLE-DAS remission demonstrating superior accuracy metrics compared with DORIS remission. No associations were observed with the mental component summary for any remission or LDA criteria. Regarding the EuroQol-5D, no correlations were identified with DORIS remission; however, correlations were observed with other remissions and LDA criteria. Conclusion: Remission and LDA criteria based on the safety of oestrogens in lupus erythematosus national assessment SLE disease activity index and SLE-DAS exhibited similar associations with PROs. SLE-DAS remission and LDA represent valid treatment targets in a T2T approach, comparable to DORIS remission and LLDAS in terms of PROs.


  • Prevalence of systemic lupus erythematosus and age-stratified treatment trends in the Japanese population: A cross-sectional study based on the National Database of Health Insurance Claims

    by Masakazu Matsushita, Ryoko Sakai, Naoto Yokogawa, Masaki Shimizu, Yuzaburo Inoue, Eisuke Inoue, Ken Yamaji, Masaaki Mori, Takako Miyamae

    Objectives: The aim of this article is to investigate the prevalence of systemic lupus erythematosus (SLE) in Japan and explore its treatment regimens in different age groups. Methods: We identified patients with SLE from the National Database of Health Insurance Claims of anonymized health insurance-related information; they had disease names associated with SLE and were treated with glucocorticoids, hydroxychloroquine, or immunosuppressants. These data were used to investigate disease prevalence and profiles in Japan. Results: Of 74,277 patients with SLE, 12,816 were men (16.6%) and 61,961 were women (83.4%). Oral glucocorticoids were administered to 89.1% of patients and hydroxychloroquine to 21.4%. Regarding immunosuppressants, mycophenolate mofetil was prescribed for 49.2% of patients aged ≤14 years and tacrolimus for 35.5% of those aged 20–39 years; these rates were higher than those observed in other age groups. Conclusions: The high proportion of patients receiving treatment for comorbidities may be partially explained by the high rate of glucocorticoid use, as approval of hydroxychloroquine for the treatment of SLE was delayed in Japan. This is the first study to ascertain the prevalence of SLE and its treatment status in Japan using the National Database, thus providing useful basic data to improve the management of the disease.


  • Open Access

    Prognostic analysis of pulmonary hypertension with lung parenchymal lesion: Comparison of mortality with and without connective tissue disease

    by Yoshifumi Suzuki, Tetsutaro Nagaoka, Yuriko Terayama, Yuichi Nagata, Takashi Yoshida, Takeo Tsutsumi, Sachiko Kuriyama, Masakazu Matsushita, Yusuke Joki, Kiyoshi Takasu, et al.


  • Promoting awareness of terminology related to unmet medical needs in context of rheumatic diseases in Japan: a systematic review for evaluating unmet medical needs

    by Susumu Yamazaki, Kazushi Izawa, Masakazu Matsushita, Akinori Moriichi, Dai Kishida, Hajime Yoshifuji, Ken Yamaji, Ryuta Nishikomori, Masaaki Mori, Takako Miyamae

    To optimize patient prognosis, patient needs, including unmet needs, should be adequately assessed. However, such needs are more challenging to report and, consequently, more likely to go unmet compared with the needs reported by physicians. We aimed to determine the appropriate direction of future research on unmet medical needs in rheumatic diseases in Japan by conducting a literature review. We searched PubMed and Web of Science using 23 terms linked to unmet medical needs for major rheumatic diseases in Japan. Further, we collected articles on health-related quality of life and investigated the scales used for assessment, as well as whether the terms “unmet needs” or “unmet medical needs” were used. We identified 949 papers on 10 diseases, including systemic lupus erythematosus, systemic sclerosis, dermatomyositis, juvenile idiopathic arthritis, adult-onset Still’s disease, antiphospholipid syndrome, mixed connective tissue disease, Takayasu arteritis, Sjögren’s syndrome, and Behçet’s disease; 25 of the 949 papers were selected for full-text review. Fifteen articles on five diseases were related to health-related quality of life. The term “unmet needs” was used in only one article. Six out of 15 studies used the 36-item short form survey, whereas the scales used in other studies differed. The optimal treatment plan determined by a physician may not necessarily align with the best interests of the patient. In clinical research, cross sectional and standardized indicators of health-related quality of life should be employed along with highly discretionary questionnaires to assess and optimize resource allocation in healthcare and simultaneously achieve patient-desired outcomes.


  • Open Access

    Critical role of lectin pathway mediated by MBL-associated serine proteases in complement activation for the pathogenesis in systemic lupus erythematosus

    by Yuko Asanuma, Kazuhisa Nozawa, Masakazu Matsushita, Makio Kusaoi, Yoshiyuki Abe, Ken Yamaji, Naoto Tamura


  • Open Access

    Extra-articular Manifestations of Rheumatoid Arthritis

    by Masakazu Matsushita, Ken Yamaji, Naoto Tamura

    Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies


  • Open Access

    Diagnosis of giant cell arteritis by head-contrast three-dimensional computed tomography angiography: two case reports

    by Toshio Kawamoto, Michihiro Ogasawara, Souichiro Nakano, Yuko Matsuki−Muramoto, Masakazu Matsushita, Kenjiro Yamanaka, Ken Yamaji, Naoto Tamura

    Introduction: Temporal artery biopsy is essential for the diagnosis of giant cell arteritis. It has been shown that 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance angiography, and ultrasonography are useful for the diagnosis of giant cell arteritis. However, there are only a few reports on the usefulness of three-dimensional computed tomography angiography in the diagnosis of giant cell arteritis. We describe two cases in which giant cell arteritis was difficult to diagnose using positron emission tomography-computed tomography and magnetic resonance angiography but was diagnosed using three-dimensional computed tomography angiography, thus showing the importance of three-dimensional computed tomography angiography in the diagnosis of giant cell arteritis. Case presentation: Case 1: An 81-year-old Japanese man. Laboratory investigations revealed normocytic anemia and raised inflammatory marker levels. Slight bleeding in the right posterior pole of his eyeball and leukoma of his left cornea were observed on fundus examination. Stenosis and stoppage of the temporal artery were detected on three-dimensional computed tomography angiography. A diagnosis of giant cell arteritis was made, and he was started on orally administered prednisolone. His headache and C-reactive protein levels improved. Four weeks after glucocorticoid steroid treatment, three-dimensional computed tomography angiography revealed improvement in stenosis and stoppage of temporal artery. Case 2: A 74-year-old Japanese woman. A dose of 20 mg of prednisolone was administered and her polymyalgia and polyarthritis improved; however, her headache and ear occlusion persisted. Although vasculitis was not detected on positron emission tomography-computed tomography, stenosis and stoppage of the temporal artery were detected on computed tomography angiography. She was diagnosed as having giant cell arteritis and started on orally administered prednisolone treatment (60 mg daily). Her headache and C-reactive protein levels improved. Four weeks after glucocorticoid treatment, three-dimensional computed tomography angiography showed improvement in stenosis and stoppage of temporal artery. Conclusions: In both patients with giant cell arteritis, three-dimensional computed tomography angiography revealed improvement in stenosis and stoppage of temporal artery after glucocorticoid treatment. We conclude that computed tomography angiography along with magnetic resonance angiography, positron emission tomography-computed tomography, and ultrasonography are important for the diagnosis of giant cell arteritis.


  • Open Access

    A case of ankylosing spondylitis with concurrent Takayasu arteritis

    by Masakazu Matsushita, Shigeto Kobayashi, Kurisu Tada, Eri Hayashi, Ken Yamaji, Atsushi Amano, Naoto Tamura

    We herein report a case involving a 56-year-old man who had experienced neck and lower back pain since the age of 23 years. Ankylosing spondylitis (AS) was diagnosed at 41 years of age, and treatment with sulfasalazine was initiated. At 44 years of age, the patient developed respiratory distress on exertion and chest pain. Aortic regurgitation (AR) was diagnosed via echocardiography, and the patient presented to our hospital for close examination and treatment. Coronary computed tomography angiography revealed no lesions in the coronary artery; however, magnetic resonance angiography revealed stenotic lesions in the left common carotid artery and left subclavian artery. Based on the findings of a physical examination, fundus examination, and blood tests, the patient was diagnosed with AS with concurrent Takayasu arteritis (TA). Upon administration of steroids to alleviate inflammation caused by an autoimmune mechanism, the patient’s chest symptoms and inflammatory findings improved. AR was treated with aortic valve replacement and prosthetic blood vessel replacement, after which the patient progressed well. Intraoperative aortic biopsy revealed findings pathologically consistent with TA. Although AS with concurrent AR is well described, AS with concurrent TA, as in the present case, is rare.